1. Scrip

Biosimilar Confidence And Knowledge Needed In Europe, Say Experts

 
• By Ian Schofield

European biosimilar market penetration varies widely across the EU member states and disease groups, with different government policies on promotion, purchasing and communication leading to mistrust. The European Commission is looking to boost confidence in biosimilars to support their uptake on a much wider scale across Europe, and to get a bird's eye view of what is driving or hindering the EU market for biosimilars.

European countries

Biosimilar approvals in Europe are going from strength to strength, with 21 products currently holding an EU marketing authorization. As of July 2016, a total of 15 other biosimilar filings were under evaluation at the European Medicines Agency, many of them versions of top selling monoclonal antibody products such as AbbVie Inc.'s Humira (adalimumab) and Roche'sRituxan (rituximab).

According to Medicines for Europe, which represents firms marketing generics, biosimilars and value-added drugs, the biosimilars approved in the EU to date have generated more than 400 million patient days...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list